Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
| Omlaag ↓
  1. [verwijderd] 1 februari 2018 11:34
    Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

    Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
3 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 903,30 -0,20%
EUR/USD 1,0865 -0,35%
FTSE 100 8.237,26 -0,31%
Germany40^ 18.515,90 -0,50%
Gold spot 2.323,79 -1,15%
NY-Nasdaq Composite 16.828,67 +0,56%

Stijgers

VIVORY...
+2,96%
NX FIL...
+2,05%
RELX
+1,79%
Vastned
+1,64%
UNILEV...
+1,38%

Dalers

Alfen ...
-5,25%
PostNL
-4,28%
TomTom
-3,61%
Pharming
-3,13%
SHELL PLC
-3,09%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links